NCT01068704View on ClinicalTrials.gov

Efficacy and Safety of BMS-690514 in Combination With Letrozole to Treat Metastatic Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

June 30, 2010

Primary Completion Date

December 31, 2010

Study Completion Date

December 31, 2010

Conditions
Breast Cancer
Interventions
DRUG

BMS-690514

Tablets, Oral, 200 mg, once daily, \~ 12 months depending on response

DRUG

Lapatinib

Tablets, Oral, 1500 mg, once daily, \~ 12 months depending on response

DRUG

Letrozole

Tablets, Oral, 2.5 mg, once daily, \~ 12 months depending on response

Trial Locations (8)

34

Local Institution, Lima

5300

Local Institution, La Rioja

28030

Local Institution, Colima

76177

Us Oncology Central Pharmacy, Fort Worth

77702

Texas Oncology-Beaumont, Beaumont

79606

Texas Oncology-Abilene, Abilene

98902

Yakima Valley Memorial Hospital/North Star Lodge, Yakima

S2000DSK

Local Institution, Rosario

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY